NGM News
NGM Bio Announces Closing of Tender Offer
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
Liver drug developers outperform as U.S. awaits first NASH drug
Ionis stock jumps as MASH drug succeeds in mid-stage trial
NGM Events
No data
NGM Monitor News
No data
NGM Earnings Analysis